Home Medicine Serum DNase I activity in systemic lupus erythematosus: correlation with immunoserological markers, the disease activity and organ involvement
Article
Licensed
Unlicensed Requires Authentication

Serum DNase I activity in systemic lupus erythematosus: correlation with immunoserological markers, the disease activity and organ involvement

  • Dusan Skiljevic , Ivica Jeremic , Milos Nikolic EMAIL logo , Sladjana Andrejevic , Mirjana Sefik-Bukilica , Biljana Stojimirovic and Branka Bonaci-Nikolic
Published/Copyright: November 23, 2012
Clinical Chemistry and Laboratory Medicine
From the journal Clinical Chemistry and Laboratory Medicine Volume 51 Issue 5

Abstract

Background: Decreased activity of serum desoxyribonuclease I (DNase I) in systemic lupus erythematosus (SLE) has been reported, but its role as a biomarker in SLE is still unelucidated.

Methods: Seventy-seven SLE patients (aged 39.6±13.1 years) were studied for serum DNase I activity, levels of antinuclear (ANA), anti-dsDNA [high-avidity ELISA, conventional ELISA and indirect immunofluorescence (IIF)], anti-nucleosome, anti-histone antibodies, complement components C3 and C4. SLE disease activity was evaluated by disease activity index (SLEDAI-2K). Thirty-five patients were serologically and clinically followed for 3–12 months (mean 5.6±2.8). Thirty-seven healthy blood donors were the control group.

Results: DNase I activity in SLE patients was lower than in healthy controls (p<0.01). DNase I activity was in positive correlation with SLEDAI-2K (p<0.01), levels of ANA, anti-dsDNA, anti-nucleosome and anti-histone antibodies (p<0.01) and in negative correlation with C3 concentration (p<0.05). The highest correlation was found between DNase I activity and anti-dsDNA concentrations determined by high-avidity ELISA (r=0.624), followed by IIF (r=0.541) and conventional ELISA (r=0.405). In the follow-up study, DNase I activity also correlated with SLEDAI-2K (p<0.01). SLE patients with low DNase I activity more frequently had SLE-specific cutaneous lesions (p<0.05).

Conclusions: Monitoring of DNase I activity simultaneously with SLEDAI-2K might be a useful tool in the follow-up of SLE. An increase of DNase I activity characterized relapse in most SLE patients, although it did not reach the levels of healthy individuals. A decrease of DNase I activity in SLE flare-ups might be a functional biomarker of a subset of patients with specific dysfunction of apoptotic chromatin degradation.

Keywords: antinuclear antibodies; desoxyribonuclease I; high avidity anti-dsDNA antibodies; SLEDAI; systemic lupus erythematosus
Corresponding author: Professor Milos Nikolic, MD, PhD, Faculty of Medicine, University of Belgrade; Clinic of Dermatovenereology, Clinical Center of Serbia, Pasterova 2 11000 Belgrade, Serbia, Phone: +381 11 2642648/+381 11 36624 86, Fax: +381 11 2682652

Conflict of interest statement

Authors’ conflict of interest disclosure: The authors stated that there are no conflicts of interest regarding the publication of this article. Research funding played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

Research funding: Supported by the Ministry of Education and Science of the Republic of Serbia, Grant No 175065.

Employment or leadership: None declared.

Honorarium: None declared.

Authors’ conflict of interest disclosure: None declared.

References

1. Vyse TJ, Kotzin BL. Genetic susceptibility to systemic lupus erythematosus. Annu Rev Immunol 1998;16:261–92.10.1146/annurev.immunol.16.1.261Search in Google Scholar

2. Tsukumo S, Yasutomo K. DNase I in pathogenesis of systemic lupus erythematosus. Clin Immunol 2004;113:14–8.10.1016/j.clim.2004.05.009Search in Google Scholar

3. Davidson A, Diamond B. Autoimmune diseases. N Engl J Med 2001;345:340–50.10.1056/NEJM200108023450506Search in Google Scholar

4. Yasutomo K. Pathological lymphocyte activation by defective clearance of self-ligands in systemic lupus erythematosus. Rheumatology (Oxford) 2003;42:214–22.10.1093/rheumatology/keg081Search in Google Scholar

5. Kyttaris VC, Juang YT, Tsokas G. Immune cells and cytokines in SLE: an update. Curr Opin Rheumatol 2005;17:518–22.10.1097/01.bor.0000170479.01451.abSearch in Google Scholar

6. Mok CC, Lau CS. Pathogenesis of systemic lupus erythematosus. J Clin Pathol 2003;56:481–90.10.1136/jcp.56.7.481Search in Google Scholar

7. Herrmann M, Voll RE, Zoller OM, Hagenhofer M, Ponner BB, Kalden JR. Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum 1998;41:1241–50.10.1002/1529-0131(199807)41:7<1241::AID-ART15>3.0.CO;2-HSearch in Google Scholar

8. Graham KL, Utz PJ. Sources of autoantigens in systemic lupus erythematosus. Curr Opin Rheumatol 2005;17:513–7.10.1097/01.bor.0000171215.87993.6bSearch in Google Scholar

9. Napirei M, Karsunky H, Zevnik B, Stephan H, Mannherz HG, Möröy T. Features of systemic lupus erythematosus in DNase I 1-deficient mice. Nat Genet 2000;25:177–81.10.1038/76032Search in Google Scholar

10. Napirei M, Wulf S, Mannherz HG. Chromatin breakdown during necrosis by serum DNase I 1 and the plasminogen system. Arthritis Rheum 2004;50:1873–83.10.1002/art.20267Search in Google Scholar

11. Mannherz HG, Peitsch MC, Zanotti S, Paddenberg R, Polzar B. A new function for an old enzyme: the role of DNase I in apoptosis. Curr Top Microbiol Immunol 1995;198:161–74.10.1007/978-3-642-79414-8_10Search in Google Scholar

12. Enari M, Sakahira H, Yokoyama H, Okawa K, Iwamatsu A, Nagata S. A caspase- activated DNase I that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 1998; 391:43–50.10.1038/34112Search in Google Scholar

13. Lacks SA. Deoxyribonuclease I in mammalian tissues: specificity of inhibition by actin. J Biol Chem 1981;256:2644–8.10.1016/S0021-9258(19)69662-6Search in Google Scholar

14. Takeshita H, Yasuda T, Nakajima T, Hosomi O, Nakashima Y, Kishi K. Mouse deoxyribonuclease I (DNase I): biochemical and immunological characterization, cDNA structure and tissue distribution. Biochem Mol Biol Int 1997;42:65–75.10.1080/15216549700202441Search in Google Scholar PubMed

15. Chitrabamrung S, Rubin RL, Tan EM. Serum deoxyribonuclease I and clinical activity in systemic lupus erythematosus. Rheumatol Int 1981;1:55–60.10.1007/BF00541153Search in Google Scholar PubMed

16. Martinez-Valle F, Balada E, Ordi-Ros J, Bujan-Rivas S, Sellas-Fernandez A, Vilardell-Tarres M. DNase I activity in patients with systemic lupus erythematosus: relationship with epidemiological, clinical, immunological and therapeutical features. Lupus 2009;18:418–23.10.1177/0961203308098189Search in Google Scholar PubMed

17. Martinez-Valle F, Balada E, Ordi-Ros J, Bujan-Rivas S, Sellas-Fernandez A, Vilardell-Tarres M. DNase I activity in systemic lupus erythematosus patients with and without nephropathy. Rheumatol Int 2010;30:1601–4.10.1007/s00296-009-1199-6Search in Google Scholar PubMed

18. Martínez Valle F, Balada E, Ordi-Ros J, Vilardell-Tarres M. DNase I and systemic lupus erythematosus. Autoimmun Rev 2008;7:359–63.10.1016/j.autrev.2008.02.002Search in Google Scholar PubMed

19. Yasutomo K, Horiuchi T, Kagami S, Tsukamoto H, Hashimura C, Urushihara M, et al. Mutation of DNase I in people with systemic lupus erythematosus. Nat Genet 2001;28:313–4.10.1038/91070Search in Google Scholar PubMed

20. Sallai K, Nagy E, Derfalvy B, Müzes G, Gergely P. Antinucleosome antibodies and decreased deoxyribonuclease activity in sera of patients with systemic lupus erythematosus. Clin Diagn Lab Immunol 2005;12:56–9.10.1128/CDLI.12.1.56-59.2005Search in Google Scholar PubMed PubMed Central

21. Hochberg MC. Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.10.1002/art.1780400928Search in Google Scholar PubMed

22. Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002;29:288–91.Search in Google Scholar

23. Romero-Díaz J, Vargas-Vóracková F, Kimura-Hayama E, Cortázar-Benítez LF, Gijón-Mitre R, Criales S, et al. Systemic lupus erythematosus risk factors for coronary artery calcifications. Rheumatology 2012;51:110–9.10.1093/rheumatology/ker307Search in Google Scholar PubMed

24. Licht R, Dieker JW, Jacobs CW, Tax WJ, Berden JH. Decreased phagocytosis of apoptotic cells in diseased SLE mice. J Autoimmun 2004;22:139–45.10.1016/j.jaut.2003.11.003Search in Google Scholar PubMed

25. Dieker JW, van der Vlag J, Berden JH. Triggers for anti-chromatin autoantibody production in SLE. Lupus 2002;11:856–64.10.1191/0961203302lu307rrSearch in Google Scholar PubMed

26. Gaipl US, Sheriff A, Franz S, Munoz LE, Voll RE, Kalden JR, et al. Inefficient clearance of dying cells and autoreactivity. Curr Top Microbiol Immunol 2006;305:161–76.10.1007/3-540-29714-6_8Search in Google Scholar PubMed

27. Casciola-Rosen LA, Anhalt G, Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 1994;179:1317–30.10.1084/jem.179.4.1317Search in Google Scholar PubMed PubMed Central

28. Michlewska S, McColl A, Rossi AG, Megson IL, Dransfield I. Clearance of dying cells and autoimmunity. Autoimmunity 2007;40:267–73.10.1080/08916930701357208Search in Google Scholar PubMed

29. Voll RE, Herrmann M, Roth EA, Stach C, Kalden JR, Girkontaite I. Immunosuppressive effects of apoptotic cells. Nature 1997;390:350–1.10.1038/37022Search in Google Scholar PubMed

30. Macanovic M, Lachmann PJ. Measurement of deoxyribonuclease I (DNase I ) in the serum and urine of systemic lupus erythematosus(SLE)-prone NZB/NZW mice by a new radial enzyme diffusion assay. Clin Exp Immunol 1997;108:220–6.10.1046/j.1365-2249.1997.3571249.xSearch in Google Scholar PubMed PubMed Central

31. Hakkim A, Fürnrohr BG, Amann K, Laube B, Abed UA, Brinkmann V, et al. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci USA 2010;107:9813–8.10.1073/pnas.0909927107Search in Google Scholar PubMed PubMed Central

32. Tew MB, Johnson RW, Reveille JD, Tan FK. A molecular analysis of the low serum deoxyribonuclease activity in lupus patients. Arthritis Rheum 2001;44:2446–7.10.1002/1529-0131(200110)44:10<2446::AID-ART409>3.0.CO;2-USearch in Google Scholar

33. Balada E, Ordi-Ros J, Hernanz S, Villarreal J, Cortés F, Vilardell-Tarrés M, et al. DNASE I mutation and systemic lupus erythematosus in a Spanish population: comment on the article by Tew, et al. Arthritis Rheum 2002;46:1974–6; author reply 1976–7.10.1002/art.10349Search in Google Scholar

34. Chakraborty P, Kacem HH, Makni-Karray K, Jarraya F, Hachicha J, Ayadi H. The A/T mutation in exon 2 of the DNASE I 1 gene is not present in Tunisian patients with systemic lupus erythematosus or in healthy subjects. Arthritis Rheum 2003;48:3297–8.10.1002/art.11318Search in Google Scholar

35. Simmonds MJ, Heward JM, Kelly MA, Allahabadia A, Foxall H, Gordon C, et al. A nonsense mutation in exon 2 of the DNase I gene is not present in UK subjects with systemic lupus erythematosus and Graves’ disease: comment on the article by Rood et al. Arthritis Rheum 2002;46:3109–10.10.1002/art.10414Search in Google Scholar

36. Lazarides E, Lindberg U. Actin is the naturally occurring inhibitor of deoxyribonuclease I. Proc Natl Acad Sci USA 1974;71:4742–6.10.1073/pnas.71.12.4742Search in Google Scholar

37. Frost PG, Lachmann PJ. The relationship of desoxyribonuclease inhibitor levels in human sera to the occurrence of antinuclear antibodies. Clin Exp Immunol 1968;3:447–55.Search in Google Scholar

38. Yeh TM, Chang HC, Liang CC, Wu JJ, Liu MF. Deoxyribonuclease-inhibitory antibodies in systemic lupus erythematosus. J Biomed Sci 2003;10:544–51.10.1007/BF02256116Search in Google Scholar

39. Bartoloni E, Ludovini V, Alunno A, Pistola L, Bistoni O, Crinò L, et al. Increased levels of circulating DNA in patients with systemic autoimmune diseases: a possible marker of disease activity in Sjögren's syndrome. Lupus 2011;20:928–35.10.1177/0961203311399606Search in Google Scholar

40. Baranovskii AG, Buneva VN, Nevinsky GA. Human deoxyribonucleases. Biochemistry (Mosc) 2004;69:587–601.10.1023/B:BIRY.0000033731.50496.01Search in Google Scholar

41. Shuster AM, Gololobov GV, Kvashuk OA, Bogomolova AE, Smirnov IV, Gabibov AG. DNA hydrolyzing autoantibodies. Science 1992;256:665–7.10.1126/science.1585181Search in Google Scholar

42. Nevzorova TA, Temnikov DA, Vinter VG. Special features of the DNA-hydrolyzing activity of the antibodies in systemic lupus erythematosus. Biochemistry (Mosc) 2003;68:1300–6.10.1023/B:BIRY.0000011650.48894.7eSearch in Google Scholar

43. Drosera M, Facchetti F, Landolfo S, Mondini M, Nyberg F, Parodi A, et al. Role of soluble and cell surface molecules in the pathogenesis of autoimmune skin diseases. Clin Exp Rheumatol 2006;24(1 Suppl 40):S7–13.Search in Google Scholar

44. Hedberg A, Fismen S, Fenton KA, Mortensen ES, Rekvig OP. Deposition of chromatin-IgG complexes in skin of nephritic MRL-lpr/lpr mice is associated with increased local matrix metalloprotease activities. Exp Dermatol 2010;19:e265–74.10.1111/j.1600-0625.2010.01064.xSearch in Google Scholar

45. Lahm A, Suck D. DNase I-induced DNA conformation. 2 A structure of a DNase I-octamer complex. J Mol Biol 1991;222:645–67.10.1016/0022-2836(91)90502-WSearch in Google Scholar

46. Weston SA, Lahm A, Suck D. X-ray structure of the DNase I-d(GGTATACC)2 complex at 2.3 A resolution. J Mol Biol 1992;226:1237–56.10.1016/0022-2836(92)91064-VSearch in Google Scholar

47. Manderson AP, Carlucci F, Lachmann PJ, Lazarus RA, Festenstein RJ, Cook HT, et al. The in vivo expression of actin/salt-resistant hyperactive DNase I inhibits the development of anti-ssDNA and anti-histone autoantibodies in a murine model of systemic lupus erythematosus. Arthritis Res Ther 2006;8:R68.10.1186/ar1936Search in Google Scholar PubMed PubMed Central

Received: 2012-8-14
Accepted: 2012-10-22
Published Online: 2012-11-23
Published in Print: 2013-05-01

©2013 by Walter de Gruyter Berlin Boston

Articles in the same Issue

  1. Masthead
  2. Masthead
  3. Editorial
  4. Progress towards standardization: an IFCC Scientific Division Perspective
  5. Review
  6. Quantitative Clinical Chemistry Proteomics (qCCP) using mass spectrometry: general characteristics and application
  7. Mini Reviews
  8. Analytical goals for the determination of HbA2
  9. Glucose meters – fit for clinical purpose
  10. Opinion Papers
  11. Metrological traceability – a concept for standardization in laboratory medicine
  12. Recommendations for clinical laboratory science reports regarding properties, units, and symbols: the NPU format1)
  13. “Good samples make good assays” – the problem of sourcing clinical samples for a standardization project
  14. Defining acceptable limits for the metrological traceability of specific measurands
  15. Original Articles
  16. A reference system for urinary albumin: current status
  17. Toward standardization of carbohydrate-deficient transferrin (CDT) measurements: III. Performance of native serum and serum spiked with disialotransferrin proves that harmonization of CDT assays is possible
  18. External Quality Assessment Scheme for reference laboratories – review of 8 years’ experience
  19. Utility of a panel of sera for the alignment of test results in the worldwide multicenter study on reference values
  20. Protocol and standard operating procedures for common use in a worldwide multicenter study on reference values
  21. Guidelines and Recommendations
  22. 2013 update on the worldwide standardization of the hemoglobin A1c measurement
  23. General Clinical Chemistry and Laboratory Medicine
  24. Evacuated blood-collection tubes for haematological tests – a quality evaluation prior to their intended use for specimen collection
  25. Refrigeration is not necessary for measurement of uric acid in patients treated with rasburicase
  26. Procalcitonin and mid-regional pro-adrenomedullin test combination in sepsis diagnosis
  27. Cysteinyl leukotrienes in exhaled breath condensate of smoking asthmatics
  28. Helicobacter pylori serology in autoimmune diseases – fact or fiction?
  29. Serum DNase I activity in systemic lupus erythematosus: correlation with immunoserological markers, the disease activity and organ involvement
  30. Antibodies against Nε-homocysteinylated proteins in patients on different methods of renal replacement therapy
  31. Reference Values and Biological Variations
  32. Reference values for urinary neutrophil gelatinase-associated lipocalin (NGAL) in pediatric age measured with a fully automated chemiluminescent platform
  33. High biological variation of serum hyaluronic acid and Hepascore, a biochemical marker model for the prediction of liver fibrosis
  34. Cardiovascular Diseases
  35. Circulating matrix Gla protein: a potential tool to identify minor carotid stenosis with calcification in a risk population
  36. Midregional pro-atrial natriuretic peptide in the general population/Insights from the Gutenberg Health Study
  37. Letters to the Editor
  38. Relationship between Helicobacter pylori infection and autoimmune disorders
  39. Rapid simultaneous genotyping of polymorphisms in ADH1B and ALDH2 using high resolution melting assay
  40. Comparison of biological specimens and DNA collection methods for PCR amplification and microarray analysis
  41. Transferrin/log(ferritin) ratio: a self-fulfilling prophecy when iron deficiency is defined by serum ferritin concentration
  42. Response to: Transferrin/log(ferritin) ratio: a self-fulfilling prophecy when iron deficiency is defined by serum ferritin concentration
  43. Determinants of homocysteine concentrations in mother and neonatal girl pairs
  44. Cysteine analog breaks cryoprecipitate associated with chronic hepatitis C
  45. Cut-off values of serum growth hormone (GH) in pharmacological stimulation tests (PhT) evaluated in short-statured children using a chemiluminescent immunometric assay (ICMA) calibrated with the International Recombinant Human GH Standard 98/574
  46. Normalized MEDx chart as a useful tool for evaluation of analytical quality achievements. A picture is worth a thousand words
  47. Harmonization of immunoassays to the all-procedure trimmed mean – proof of concept by use of data from the insulin standardization project
  48. Congress Abstracts
  49. Annual Assembly of the Swiss Society of Clinical Chemistry & International Congress of Porphyrins and Porphyrias & International Meeting of Porphyria Patients: Personalized Medicine and Rare Diseases
https://doi.org/10.1515/cclm-2012-0521
Keywords for this article
antinuclear antibodies; desoxyribonuclease I; high avidity anti-dsDNA antibodies; SLEDAI; systemic lupus erythematosus

Articles in the same Issue

  1. Masthead
  2. Masthead
  3. Editorial
  4. Progress towards standardization: an IFCC Scientific Division Perspective
  5. Review
  6. Quantitative Clinical Chemistry Proteomics (qCCP) using mass spectrometry: general characteristics and application
  7. Mini Reviews
  8. Analytical goals for the determination of HbA2
  9. Glucose meters – fit for clinical purpose
  10. Opinion Papers
  11. Metrological traceability – a concept for standardization in laboratory medicine
  12. Recommendations for clinical laboratory science reports regarding properties, units, and symbols: the NPU format1)
  13. “Good samples make good assays” – the problem of sourcing clinical samples for a standardization project
  14. Defining acceptable limits for the metrological traceability of specific measurands
  15. Original Articles
  16. A reference system for urinary albumin: current status
  17. Toward standardization of carbohydrate-deficient transferrin (CDT) measurements: III. Performance of native serum and serum spiked with disialotransferrin proves that harmonization of CDT assays is possible
  18. External Quality Assessment Scheme for reference laboratories – review of 8 years’ experience
  19. Utility of a panel of sera for the alignment of test results in the worldwide multicenter study on reference values
  20. Protocol and standard operating procedures for common use in a worldwide multicenter study on reference values
  21. Guidelines and Recommendations
  22. 2013 update on the worldwide standardization of the hemoglobin A1c measurement
  23. General Clinical Chemistry and Laboratory Medicine
  24. Evacuated blood-collection tubes for haematological tests – a quality evaluation prior to their intended use for specimen collection
  25. Refrigeration is not necessary for measurement of uric acid in patients treated with rasburicase
  26. Procalcitonin and mid-regional pro-adrenomedullin test combination in sepsis diagnosis
  27. Cysteinyl leukotrienes in exhaled breath condensate of smoking asthmatics
  28. Helicobacter pylori serology in autoimmune diseases – fact or fiction?
  29. Serum DNase I activity in systemic lupus erythematosus: correlation with immunoserological markers, the disease activity and organ involvement
  30. Antibodies against Nε-homocysteinylated proteins in patients on different methods of renal replacement therapy
  31. Reference Values and Biological Variations
  32. Reference values for urinary neutrophil gelatinase-associated lipocalin (NGAL) in pediatric age measured with a fully automated chemiluminescent platform
  33. High biological variation of serum hyaluronic acid and Hepascore, a biochemical marker model for the prediction of liver fibrosis
  34. Cardiovascular Diseases
  35. Circulating matrix Gla protein: a potential tool to identify minor carotid stenosis with calcification in a risk population
  36. Midregional pro-atrial natriuretic peptide in the general population/Insights from the Gutenberg Health Study
  37. Letters to the Editor
  38. Relationship between Helicobacter pylori infection and autoimmune disorders
  39. Rapid simultaneous genotyping of polymorphisms in ADH1B and ALDH2 using high resolution melting assay
  40. Comparison of biological specimens and DNA collection methods for PCR amplification and microarray analysis
  41. Transferrin/log(ferritin) ratio: a self-fulfilling prophecy when iron deficiency is defined by serum ferritin concentration
  42. Response to: Transferrin/log(ferritin) ratio: a self-fulfilling prophecy when iron deficiency is defined by serum ferritin concentration
  43. Determinants of homocysteine concentrations in mother and neonatal girl pairs
  44. Cysteine analog breaks cryoprecipitate associated with chronic hepatitis C
  45. Cut-off values of serum growth hormone (GH) in pharmacological stimulation tests (PhT) evaluated in short-statured children using a chemiluminescent immunometric assay (ICMA) calibrated with the International Recombinant Human GH Standard 98/574
  46. Normalized MEDx chart as a useful tool for evaluation of analytical quality achievements. A picture is worth a thousand words
  47. Harmonization of immunoassays to the all-procedure trimmed mean – proof of concept by use of data from the insulin standardization project
  48. Congress Abstracts
  49. Annual Assembly of the Swiss Society of Clinical Chemistry & International Congress of Porphyrins and Porphyrias & International Meeting of Porphyria Patients: Personalized Medicine and Rare Diseases
Sign up now to receive a 20% welcome discount
Institutional Access
How does access work?
Have an idea on how to improve our website?
Please write us.
© 2026 De Gruyter Brill
Downloaded on 27.2.2026 from https://www.degruyterbrill.com/document/doi/10.1515/cclm-2012-0521/html
Scroll to top button